Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study, Journal of Clinical Oncology, vol.30, issue.18, pp.2190-2196, 2012. ,
DOI : 10.1200/JCO.2011.38.0402
Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels, Blood, vol.124, issue.19, pp.2983-2986, 2014. ,
DOI : 10.1182/blood-2014-07-584953
CD30 expression in peripheral T-cell lymphomas, Haematologica, vol.98, issue.8, pp.81-82, 2013. ,
DOI : 10.3324/haematol.2013.084913
URL : http://doi.org/10.3324/haematol.2013.084913
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin, Blood, vol.123, issue.20, pp.3095-3100, 2014. ,
DOI : 10.1182/blood-2013-12-542142
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425442
Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis, Journal of Clinical Oncology, vol.33, issue.32, pp.3759-3765, 2015. ,
DOI : 10.1200/JCO.2014.60.3787
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and S??zary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project, Journal of Clinical Oncology, vol.33, issue.32, pp.3750-3758, 2015. ,
DOI : 10.1200/JCO.2014.60.3969
International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes, J Clin Oncol, vol.26, issue.25, pp.4124-4130, 2008. ,
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project, Blood, vol.111, issue.12, pp.5496-5504, 2008. ,
DOI : 10.1182/blood-2008-01-134270
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors, Journal of Clinical Oncology, vol.31, issue.16, pp.311970-1976, 2013. ,
DOI : 10.1200/JCO.2012.44.7524
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression, Blood, vol.125, issue.9, pp.1394-1402, 2015. ,
DOI : 10.1182/blood-2014-09-598763
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma, Leukemia & Lymphoma, vol.2013, issue.1, pp.703-710, 2015. ,
DOI : 10.1182/blood-2012-03-418673
Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma, Blood, vol.124, issue.21, 2014. ,